BLA 125276/S-127
BLA 125472/S-040

SUPPLEMENT APPROVAL

Hoffman-La Roche Inc.
c/o Genentech, Inc.
1 DNA Way
Bldg 35, MS 5F
South San Francisco, CA 94080

Attention: Michael Woods, PharmD, RAC
Regulatory Program Management

Dear Dr. Woods:

Please refer to your supplemental biologics license applications (sBLAs), dated April 18, 2019, and your amendments, submitted under section 351(a) of the Public Health Service Act for Actemra (tocilizumab) for Intravenous Injection, 80 mg/4 mL, 200 mg/10 mL and 400 mg/20 mL and Actemra (tocilizumab) for Subcutaneous Injection, 162 mg/0.9 mL.

We also refer to our letter dated March 20, 2019, notifying you under Section 505(0)(4) of the FDCA, of new safety information that we believe should be included in the labeling for Actemra (tocilizumab). This information pertains to the association between Actemra (tocilizumab) use and drug-induced liver injury (DILI).

These supplemental biologics license applications provide for revisions to the labeling for Actemra (tocilizumab), consistent with our March 20, 2019, SAFETY LABELING CHANGE NOTIFICATION letter, and information requests dated May 13 and 28, 2019.

APPROVAL & LABELING

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF HIGHLIGHTS ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov,[1] that is identical to the enclosed labeling text for the Prescribing Information, Medication Guide, and Instructions for Use and include the labeling changes proposed in any pending "Changes Being Effected" (CBE) supplements.

Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.[2]

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for these BLAs, including pending "Changes Being Effected" (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in Microsoft Word format that includes the changes approved in these supplemental applications, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your applications, you are exempt from this requirement.

[1] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm

[2] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, call Carol F. Hill, Senior Regulatory Health Project Manager for Safety, at 301-796-1226.

Sincerely,

{See appended electronic signature page}

Sally Seymour, MD
Deputy Director for Safety
Division of Pulmonary, Allergy, and
Rheumatology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURES:
Content of Labeling
Prescribing Information
Medication Guide
Instructions for Use

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

SALLY M SEYMOUR
06/11/2019 09:20:21 AM